

Cardiac Glycosides and drugs for heart failure

DR. MAULIN MEHTA



Contents

1. Introduction
2. Cardiac glycosides
3. Treatment of heart failure

Introduction


- Heart fails to pump blood to the body for normal functions
- Systolic/diastolic dysfunction
- Produces congestive symptoms like
 - Venous engorgement, edema, enlargement of liver, dyspnoea, oliguria

-
- Glycosides: by improving CO,
reduces cardiac work and O₂ demand
 - Other newer drugs added

Cardiac glycosides

- William withering
- Foxglove (digitalis)
- Sources of cardiac glycosides:
 - Digitalis lanata=digoxin
 - Digitalis purpurea=digitoxin; not useful

Chemical structure



- Aglycone along with sugar moieties
- Aglycone:- pharmacological activity
- Sugar:- modify solubility and permeability

Pharmacological actions

Digoxin is prototype drug


1. Heart:-


- Force of contraction:- increase dose dependent inotropic effect

Cardiac output:- increases


- Heart rate:- **decreases**
 - Both vagal (direct stimulation) and extra-vagal action (direct depressant on SA node and AV node)
 - Vagal action can be blocked by atropine

Stroke volume Vs Arterial Impedance





Mechanism of action



2. Blood vessels

- Constriction, but not much of effect. No significant effect on coronary circulation

3. Kidney

- Diuresis increases due to improved circulation

4. CNS

- Higher doses:- **CTZ stimulation**

Pharmacokinetics

- Lipid soluble:- digitoxin (Liver)
- Food affects both (Delays absorption)
- Common:
 - Large volume of distribution (concentrated in heart, liver, kidney, skeletal muscle)
 - T_{1/2}: 40 hours
 - Steady state levels and full therapeutic effect after long time
 - Cumulative drug

Adverse effects

Narrow therapeutic index

Extra cardiac:

- Nausea, vomiting, abdominal pain

Due to gastric irritation, mesenteric vasoconstriction and CTZ stimulation

- Fatigue, malaise, headache, mental confusion, disorientation, psychosis
- Visual disturbances

Cardiac

- Arrhythmia:- pulsus bigeminus, ventricular extra-systole, tachycardia and fibrillation
- Partial or complete AV block

Extra cardiac symptoms generally proceed to cardiac

Treatment:- stop digitalis, nothing much in case of extra-cardiac

- 1) For tachyarrhythmias:-
 - Infuse IV KCl 20 mmol/hour
- 2) For ventricular arrhythmias:-
 - Lidocaine IV
- 3) For supraventricular:-
 - Propranolol
- 4) For A-V block
 - Atropine 0.6 to 1.2 mg IM
 - **Digibind**:- 38 mg vial; digoxin specific antibody; given IV

Drug drug interactions

1. Diuretics
2. Calcium
3. Quinidine, Verapamil
4. Adrenergic drugs
5. Metoclopramide, antacids
6. Propranolol, verapamil, diltiazem

Therapeutic uses

1. Congestive heart failure (CHF)

- Dosing pattern
- 1) Slow digitalization:-
 - Maintenance dose 0.125-0.25 mg/day given from beginning
 - Takes one week for response
 - Gradually increase to 0.375, 0.5 mg weekly
 - Relief of symptoms
 - bradycardia:- sign to stop the drug

2) Rapid digitalization:-

- 0.5 to 1.0 mg stat followed by 0.25 mg every 6 hourly
- Takes 6-24 hours
- Not practiced now

2. Cardiac arrhythmias

- Atrial fibrillation:- control ventricular rate
- Atrial flutter (200-350 beats/min) less than AF
- Paroxysmal supraventricular tachycardia (150-200/min)

Reference

Author	Result	Journal	Level
Ioana Dumitru	Out of 2891 patients, 1) 18% of whom initiated treatment with digoxin, incident digoxin use was associated with significantly higher rates of death 2) Digoxin use was not associated with a significant difference in the risk of hospitalization for heart failure	Medscape	Level 1

Thank you

